Provided by Tiger Trade Technology Pte. Ltd.

Tourmaline Bio

47.98
0.0000
Volume:- -
Turnover:37.61M
Market Cap:1.24B
PE:-13.97
High:47.98
Open:47.98
Low:47.98
Close:47.98
52wk High:48.27
52wk Low:11.56
Shares:25.76M
Float Shares:13.12M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4351
EPS(LYR):-2.8882
ROE:-29.62%
ROA:-20.85%
PB:4.77
PE(LYR):-16.61

Loading ...

Company Profile

Company Name:
Tourmaline Bio
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was incorporated in 2002 and is based in New York, New York.